LegoChem Bio

Ligochem Bio (formerly LegoChem Biosciences) is a clinical-stage biopharmaceutical company based in South Korea, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company's proprietary ConjuAll platform enables the creation of site-specific, stable ADCs with improved therapeutic indices compared to traditional technologies. Ligochem Bio has established a robust pipeline targeting various oncology markers, including TROP2, HER2, and ROR1, and has secured significant global licensing deals with major pharmaceutical companies like Janssen and Amgen. Beyond ADCs, the company also develops small molecule therapeutics for infectious diseases and fibrotic conditions. The company is publicly traded on the KOSDAQ and continues to expand its global footprint through its US-based subsidiary.